<DOC>
	<DOCNO>NCT00499239</DOCNO>
	<brief_summary>Multi-center , open-label , single-dose , dose-escalating Phase I/II study GS 9219 adult patient relapse refractory CLL , NHL MM . Patients enrol study sequential dose cohort . Patients administer single IV infusion GS 9219 Day 1 21 day cycle may receive total six treatment cycle base toxicity response . Patients demonstrate disease progression discontinue study . Patients , completion six treatment cycle , tolerate treatment show evidence disease control ( response stabilization ) eligible continue receive treatment dose .</brief_summary>
	<brief_title>A Trial GS-9219 Chronic Lymphocytic Leukemia ( CLL ) , Non-Hodgkin 's Lymphoma ( NHL ) Multiple Myeloma ( MM )</brief_title>
	<detailed_description>The primary objective study follow : To assess safety , toxicity , maximum tolerate dose ( MTD ) GS 9219 administer via IV administration every three week ( 21 day ) six treatment cycle , i.e . total 18 week , patient relapse refractory Chronic Lymphocytic Leukemia ( CLL ) , Non-Hodgkin 's Lymphoma ( NHL ) Multiple Myeloma ( MM ) . The secondary objective study follow : To determine pharmacokinetic parameter GS 9219 regimen patient population . To assess antitumor activity GS 9219 base Response Rate Duration Response . Progression-free Survival Overall Survival assess applicable .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<criteria>Relapsed refractory CLL , NHL MM ECOG Performance Status 0 , 1 , 2 Adequate organ function ( protocol define ) ECG without evidence clinically significant ventricular arrhythmia AIDSrelated lymphoma Subjects NHL present exclusively nonmeasurable lesion Subjects MM nonsecretory and/or nonmeasurable disease Recent anticancer therapy ( chemotherapy , radiotherapy , and/or biotherapy ) within four week prior start treatment Evidence pulmonary fibrosis Other concurrent malignancy Uncontrolled concurrent illness Receiving chronic , systemically administered steroid Known hypersensitivity nucleoside analogue</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Hematologic Malignancies</keyword>
	<keyword>CLL</keyword>
	<keyword>NHL</keyword>
	<keyword>Chronic Lymphocytic Leukemia</keyword>
	<keyword>Non-Hodgkin 's Lymphoma</keyword>
	<keyword>CLL NHL</keyword>
	<keyword>Multiple Myeloma</keyword>
	<keyword>MM</keyword>
</DOC>